Devices Must Show Best Clinical Outcomes Under ACO, Medical Home Pilots
This article was originally published in The Gray Sheet
Executive Summary
Device makers will be under increased pressure to prove that their products provide the best clinical outcomes among alternatives as CMS tests out new reimbursement models under the health care reform law
You may also be interested in...
CMS Plans To Draft Accountable Care Organization Regulations This Fall
Physicians, hospital associations and patient advocates want more opportunities to present their views as CMS moves forward with its accountable care organization demonstration projects as required by the new health care reform law
CMS Plans To Draft Accountable Care Organization Regulations This Fall
Physicians, hospital associations and patient advocates want more opportunities to present their views as CMS moves forward with its accountable care organization demonstration projects as required by the new health care reform law
CMS In Brief
Coverage with evidence for stem cell transplants?: CMS proposes May 6 to allow coverage with evidence development for allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome, a group of diverse blood disorders in which the bone marrow does not produce enough healthy, functioning blood cells (1"The Gray Sheet" Nov. 30, 2009). The proposed coverage memo outlines criteria for prospective controlled clinical studies, including the need to address specified treatment outcomes and to adhere to strict standards of scientific integrity. CMS is taking comments through June 5 and plans a final rule by Aug. 4